REMARKS

The Commissioner is hereby authorized to charge any fees associated with this response or credit any overpayment to Deposit Account No. 13-3402.

Respectfully submitted,

Anthony J. Zelano Reg. No. 27,969
Attorney for Applicant(s)

MILLEN, WHITE, ZELANO
& BRANIGAN, P.C.
Arlington Courthouse Plaza 1, Suite 1400
2200 Clarendon Boulevard
Arlington, Virginia 22201
Telephone: (703) 243-6333
Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2396

Date: May 31, 2002

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE CLAIMS:

Please amend the claims as follows:

1. (Amended) [Compounds] A compound of the formula I



I

in which

R^1[,] and R^2 [in each case] are each, independently of one another, [are] H, A, OH, OA or Hal,

R^1 and R^2 together are alternatively [also] alkylene having 3-5 [C] carbon atoms, $-O-CH_2-CH_2-$, $-CH_2-O-CH_2-$, $-O-CH_2-O-$ or $-O-CH_2-CH_2-O-$,

R^3[,] and R^4 [in each case] are each, independently of one another, [are] H or A,

X is R^5, R^6 or R^7 monosubstituted by R^8,

R^5 is linear or branched alkylene having 1-10 [C] carbon atoms, in which one or two CH_2 groups [can] may be replaced by -CH=CH- groups, O, S or SO,

R^6 is cycloalkyl or cycloalkylalkylene having 5-12 [C] carbon atoms,

R^7 is phenyl or phenylmethyl,

R^8 is COOH, COOA, $CONH_2$, CONHA, $CON(A)_2$ or CN,

A is alkyl having from 1 to 6 [C] carbon atoms, and

Hal is F, Cl, Br or I,

[and their] or a physiologically acceptable [salts and solvates] salt or solvate thereof.

2. (Amended) [Compounds] A compound of the formula I according to Claim 1

(a) 5-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid;

(b) 4-[7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]benzoic acid;

(c) 4-[7-(3,4-methylene[-]dioxy[-]benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]butyric acid;

(d) 5-[7-(benzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-yl]pentanoic acid;

(e) [7-(3-chloro-4-methoxybenzylamino)-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-5-ylmethoxy]acetic acid;

[and their] or a physiologically acceptable [salts and solvates] salt or solvate thereof.

3. (Amended) [Process] A process for the preparation

of [compounds] a compound of the formula I according to Claim 1 and [their] salts thereof,

[characterized in that] comprising reacting

a) a compound of the formula II



II

in which

R^3, R^4 and X [have the meanings indicated] are as defined in Claim 1,
and L is Cl, Br, OH, SCH_3 or a reactive esterified OH group,

[is reacted] with a compound of the formula III



III

in which

R^1 and R^2 [have the meanings indicated] are as defined above,

or

b) converting a radical X in a compound of the formula I[, a radical X is converted] into another radical X by[, for example,] hydrolysing an ester group to a COOH group or converting a COOH group into an amide or into a cyano group

and/or converting a compound of the formula I [is converted] into one of its salts.

4. (Amended) [Process] A process for the [production] preparation of a pharmaceutical [preparations, characterized in that] preparation, comprising converting a compound of the formula I according to Claim 1 and/or one of its physiologically acceptable salts and solvates [is brought] into a suitable [dose] dosage form together with at least one solid, liquid or semi-liquid [vehicle or] excipient or solvent.

5. (Amended) [Pharmaceutical] A pharmaceutical preparation, [characterized in that it contains] comprising at least one compound of the formula I according to Claim 1 and/or [one of its] a physiologically acceptable [salts and solvates] salt or solvate thereof.

6. (Amended) [Compounds] A compound of the formula I according to Claim 1 and [their] physiologically acceptable [salts and solvates] salt or solvate thereof for [the control of diseases] combating a disorder of the cardiovascular system and for the treatment and/or therapy of potency disorders.

8. (Amended) Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts and solvates for the [production] preparation of a medicament.

9. (Amended) [Use of compounds of the formula I according to Claim 1 and/or their physiologically acceptable salts and solvates for the production of a medicament for the control of diseases] A method of treating a disease of the cardiovascular system [and for the treatment and/or therapy of] or a potency [disorders] disorder, comprising administering a compound of claim 1.